Please assess the completion status of the following clinical trial:

Trial Title: Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with traumatic brain injury~* Glasgow Coma Score (GCS) score 3-8(inclusive),or GCS motor score of 5 or less and abnormal admission CT scan showing intracranial pathology~* Hemodynamically stable with a systolic BP \>90 mm Hg~* At least one reactive pupil~* A negative pregnancy test in females~* Age at least 18 years~* Signed informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for research form OR~* Subjects with subarachnoid hemorrhage (SAH)~* SAH documented by CT scan~* Hunt-Hess grade 3-5, inclusive~* Hemodynamically stable with a systolic BP\> 90 mm Hg~* At least one reactive pupil~* A negative pregnancy test in females~* Age of at least 18 years~* Signed informed consent and HIPAA authorization for research form~Exclusion Criteria for enrollment~* No venous access~* Spinal cord injury~* History of or CT confirmation of previous brain injury such as brain tumor, cerebral infarct, or spontaneous intracerebral hemorrhage~* Hemodynamically unstable~* Suspected anoxic events~* Other peripheral trauma likely to result in liver failure~* Positive pregnancy test in females~* Age less than 18 years of age~* Known hypersensitivity to any anticonvulsant~* An injury that, in the opinion of the principal investigator, has a high likelihood of death within the first 72 hours.~* Any treatment, condition, or injury that contraindicates treatment with LEV (levetiracetam) or phenytoin (PHT).~* Inability to obtain signed informed consent or HIPAA authorization for research.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levetiracetam (Type: ACTIVE_COMPARATOR): Group 1 - The levetiracetam (Keppra®) group will receive a loading dose of 20 mg/kg IV over 15 minutes (rounded to the nearest 250mg) up to a maximum of 2000 mg, then started on maintenance dose (1000 mg, IV BID)as prophylaxis for 7 days.
- Phenytoin (Type: ACTIVE_COMPARATOR): Group 2-The phenytoin group will receive a loading dose of 20 mg/kg IV to a maximum of 2000mg, then started on maintenance dose at 5 mg/kg/day (rounded to nearest 100mg dose, IV, divided into three doses a day) as prophylaxis for 7 days. Phenytoin levels are to be checked daily and dose adjusted as needed to maintain therapeutic levels of 10-20 µg/dL.

Based on this trial design, predict the completion outcome and termination type (if applicable).